MedPath

Savolitinib

Generic Name
Savolitinib
Drug Type
Small Molecule
Chemical Formula
C17H15N9
CAS Number
1313725-88-0
Unique Ingredient Identifier
2A2DA6857R
Background

Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.

Indication

用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。

Clinical Trials
Related News

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Phase 2
Completed
Conditions
Locally Advanced Papillary Renal Cell Carcinoma
Metastatic Papillary Renal Cell Carcinoma
Type 1 Papillary Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7
Unresectable Renal Cell Carcinoma
Type 2 Papillary Renal Cell Carcinoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
First Posted Date
2016-05-04
Last Posted Date
2025-03-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
152
Registration Number
NCT02761057
Locations
🇺🇸

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

🇺🇸

Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

🇺🇸

Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 592 locations

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Phase 2
Completed
Conditions
Advanced Gastric Adenocarcinoma
Interventions
First Posted Date
2015-05-20
Last Posted Date
2022-06-15
Lead Sponsor
Samsung Medical Center
Target Recruit Count
16
Registration Number
NCT02449551
Locations
🇰🇷

Samsung Medical center, Seoul, Korea, Republic of

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Phase 1
Completed
Conditions
Advanced Gastric Adenocarcinoma
Interventions
First Posted Date
2015-05-18
Last Posted Date
2022-06-15
Lead Sponsor
Samsung Medical Center
Target Recruit Count
7
Registration Number
NCT02447406
Locations
🇰🇷

Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Phase 2
Completed
Conditions
Advanced Gastric Adenocarcinoma
Interventions
First Posted Date
2015-05-18
Last Posted Date
2019-12-30
Lead Sponsor
Samsung Medical Center
Target Recruit Count
2
Registration Number
NCT02447380
Locations
🇰🇷

Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Phase 1
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2015-03-02
Last Posted Date
2020-04-24
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
64
Registration Number
NCT02374645
Locations
🇨🇳

Guangdong General Hospital, Guangzhou, China

A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

Phase 1
Completed
Conditions
Gastric Cancer
Interventions
First Posted Date
2014-09-30
Last Posted Date
2016-04-08
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
25
Registration Number
NCT02252913
Locations
🇨🇳

Fudan University Shanghai Cancer Hospital, Shanghai, China

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Phase 2
Completed
Conditions
Papillary Renal Cell Cancer
Interventions
First Posted Date
2014-05-01
Last Posted Date
2021-04-19
Lead Sponsor
AstraZeneca
Target Recruit Count
111
Registration Number
NCT02127710
Locations
🇬🇧

Research Site, Manchester, United Kingdom

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Drug: Standard maintenance for squamous NSCLC
First Posted Date
2014-04-17
Last Posted Date
2024-01-10
Lead Sponsor
UNICANCER
Target Recruit Count
999
Registration Number
NCT02117167
Locations
🇫🇷

Hôpital Avicenne, Bobigny, France

🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Institut Paoli Calmettes, Marseille, France

and more 34 locations

A Food Effect Phase I Study of the Volitinib in Healthy Subjects

Phase 1
Completed
Conditions
Food Effect
Health Subjects
Interventions
First Posted Date
2013-12-20
Last Posted Date
2019-05-14
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
25
Registration Number
NCT02017236
Locations
🇨🇳

Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Tumor
Interventions
First Posted Date
2013-01-21
Last Posted Date
2016-06-01
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
47
Registration Number
NCT01773018
Locations
🇦🇺

Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

🇦🇺

Austin Health, Melbourne, Australia

🇦🇺

Southern Health and Monash Institute of Medical Research, Clayton, Australia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy